iSpecimen Appoints New CMO, Elects Director

Ticker: ISPC · Form: 8-K · Filed: 2024-12-12T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-election, personnel

TL;DR

iSpecimen beefs up leadership with a new CMO and board member.

AI Summary

On December 9, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Board of Directors. The company also reported on its compensatory arrangements for certain officers.

Why It Matters

These leadership changes could signal a strategic shift or focus on medical affairs and governance for iSpecimen Inc.

Risk Assessment

Risk Level: low — The filing primarily concerns personnel appointments and board changes, which are standard corporate events.

Key Players & Entities

FAQ

What is the primary reason for Dr. Jonathan S. Roth's appointment as Chief Medical Officer?

The filing does not explicitly state the primary reason but implies a focus on medical affairs and leadership within the company.

What is Ms. Jennifer L. Jones's background or expertise that led to her election to the Board of Directors?

The filing does not provide details on Ms. Jones's background or expertise.

Are there any changes to the executive compensation structure mentioned in the filing?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but specific details of changes are not provided in the excerpt.

What is the significance of the 'Other Events' item listed in the filing?

The filing does not specify what constitutes the 'Other Events' beyond the personnel and board changes.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on December 9, 2024.

From the Filing

0001104659-24-128084.txt : 20241212 0001104659-24-128084.hdr.sgml : 20241212 20241212172624 ACCESSION NUMBER: 0001104659-24-128084 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241209 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241212 DATE AS OF CHANGE: 20241212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iSpecimen Inc. CENTRAL INDEX KEY: 0001558569 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 270480143 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40501 FILM NUMBER: 241546060 BUSINESS ADDRESS: STREET 1: 8 CABOT ROAD STREET 2: SUITE 1800 CITY: WOBURN STATE: MA ZIP: 08101 BUSINESS PHONE: 781-301-6700 MAIL ADDRESS: STREET 1: 8 CABOT ROAD STREET 2: SUITE 1800 CITY: WOBURN STATE: MA ZIP: 08101 8-K 1 tm2430967d1_8k.htm FORM 8-K false 0001558569 0001558569 2024-12-09 2024-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): December 9, 2024   iSpecimen Inc. (Exact name of registrant as specified in its charter)   Delaware   001-40501   27-0480143 (State or other jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   8 Cabot Road, Suite 1800 Woburn , MA 01801 (Address of principal executive offices, including zip code)   Registrant’s telephone number, including area code: ( 781 ) 301-6700   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ISPC   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company x   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨             Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On December 9, 2024, iSpecimen Inc. (the “Company”) entered into an Independent Contractor Agreement (the “Agreement”) with Mr. Robe

View on Read The Filing